Usefully described as a gene-editing company, GeneLancet Biosciences personnel own a novel single-molecule guide RNA (lgRNA) of distinct intellectual property, Management are developing STAR Editors (novel RGENs) for biological and therapeutic applications. STAR Editor is a CRISPR-Cas/lgRNA conjugate in development, toward an extremely low-off-target gene cutting, in-situ templated gene repairing, low/non- immunogenic and cell-targeting precise gene editor.
